Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole

World J Gastroenterol. 2008 Apr 21;14(15):2406-10. doi: 10.3748/wjg.14.2406.

Abstract

Aim: To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafutidine, a novel H2 receptor antagonist, with those of the proton pump inhibitor lansoprazole (LPZ) 30 mg.

Methods: Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug.

Results: The median intragastric pH was significantly higher in individuals who received lafutidine 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg.

Conclusion: In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidine than by LPZ.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage
  • 2-Pyridinylmethylsulfinylbenzimidazoles / pharmacokinetics
  • 2-Pyridinylmethylsulfinylbenzimidazoles / pharmacology*
  • Acetamides / administration & dosage
  • Acetamides / pharmacokinetics
  • Acetamides / pharmacology*
  • Administration, Oral
  • Adult
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Cross-Over Studies
  • Cytochrome P-450 CYP2C19
  • Gastric Acid / metabolism*
  • Gastric Acidity Determination
  • Gastric Mucosa / drug effects*
  • Gastric Mucosa / metabolism
  • Genotype
  • Histamine H2 Antagonists / administration & dosage
  • Histamine H2 Antagonists / pharmacokinetics
  • Histamine H2 Antagonists / pharmacology*
  • Humans
  • Hydrogen-Ion Concentration
  • Lansoprazole
  • Male
  • Middle Aged
  • Piperidines / administration & dosage
  • Piperidines / pharmacokinetics
  • Piperidines / pharmacology*
  • Proton Pump Inhibitors / administration & dosage
  • Proton Pump Inhibitors / pharmacokinetics
  • Proton Pump Inhibitors / pharmacology*
  • Pyridines / administration & dosage
  • Pyridines / pharmacokinetics
  • Pyridines / pharmacology*

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Acetamides
  • Histamine H2 Antagonists
  • Piperidines
  • Proton Pump Inhibitors
  • Pyridines
  • Lansoprazole
  • lafutidine
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19